Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Lung cancer is the leading cause of cancer related death, and is divided into two major
histological subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading …

Small cell lung cancer (SCLC) is a recalcitrant, relatively immune-cold, and deadly subtype
of lung cancer. SCLC has been viewed as a single or homogenous disease that includes …

Objectives Transformed small-cell lung cancer (T-SCLC) has an extremely poor prognosis,
and no remedies based on immunotherapy have been evaluated among T-SCLC patients …

In advanced lung cancer treatment, immunotherapy provides durable responses in some
patients. However, other patients experience progressive disease and the resistance …

Purpose This study aimed to determine the incidence and clinical course of epidermal
growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT) …

Histologic transformation (HT) is a major cause of drug resistance to therapy in patients with
lung cancer. HTs to small-cell lung cancer (SCLC) have been reported frequently in patients …

Transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is
rare and is associated with poor prognosis. However, the standard treatment protocols for …